Jounce Therapeutics, a clinical stage immuno-oncology biotech targeting inducible T-cell co-stimulators, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The Cambridge, MA-based company was founded in 2012 and booked $17 million in collaboration revenue for the 12 months ended September 30, 2016. It plans to list on the Nasdaq under the symbol JNCE. J.P. Morgan and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
